Literature summary for 3.4.24.23 extracted from

Wang, X.; Chow, F.L.; Oka, T.; Hao, L.; Lopez-Campistrous, A.; Kelly, S.; Cooper, S.; Odenbach, J.; Finegan, B.A.; Schulz, R.; Kassiri, Z.; Lopaschuk, G.D.; Fernandez-Patron, C.
Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy (2009), Circulation, 119, 2480-2489.

Search for more literature for 3.4.24.23

Protein Variants

Protein Variants	Comment	Organism
additional information	knockdown of MMP-7 by siRNA attenuates hypertension, inhibits ADAM-12 overexpression, and prevents cardiac hypertrophy. Resistance to acute hypertension in mice lacking active MMP-7	Mus musculus
additional information	MMP-7 gene knockout or knockdown of MMP-7 by RNA interference, results in attenuation of hypertension and stops development of cardiac hypertrophy in spontaneously hypertensive rats, and in decreased levels of myocardial ADAM-12 mRNA	Rattus norvegicus

Organism

Organism	UniProt	Comment	Textmining
Mus musculus	-	MMP-7-/- mice and age-matched C57BL/6 mice	-
Rattus norvegicus	-	Sprague Dawley rats, spontaneously hypertensive rats and age-matched Wistar-Kyoto rats	-

Posttranslational Modification

Posttranslational Modification	Comment	Organism
proteolytic modification	MMP-7 needs to be posttranslationally activated	Mus musculus
proteolytic modification	MMP-7 needs to be posttranslationally activated	Rattus norvegicus

Source Tissue

Source Tissue	Comment	Organism	Textmining
heart	-	Rattus norvegicus	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
casein + H2O	non-specific substrate used in zymography	Rattus norvegicus	?	-	?

Synonyms

Synonyms	Comment	Organism
Matrix metalloproteinase-7	-	Mus musculus
Matrix metalloproteinase-7	-	Rattus norvegicus
MMP-7	-	Mus musculus
MMP-7	-	Rattus norvegicus

General Information

General Information	Comment	Organism
additional information	MMP-7 expression regulation, high expression of ADAM-12 observed under sustained agonist stimulation acts in a negative feedback loop to inhibit MMP-7 transcription, overview	Mus musculus
additional information	MMP-7 expression regulation, high expression of ADAM-12 observed under sustained agonist stimulation acts in a negative feedback loop to inhibit MMP-7 transcription, overview	Rattus norvegicus
physiological function	MMP-7 controls the transcription of the disintegrin and metalloproteinase-12, ADAM-12, the major metalloproteinase implicated in cardiac hypertrophy. Matrix metalloproteinase-7 and ADAM-12 form a novel signaling axis in a variety of cardiovascular processes, including hypertension and hypertrophy, overview. Induction of acute hypertension by vasoconstrictors, i.e. catecholamines, angiotensin II, and the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester, require the posttranscriptional activation of vascular MMP-7. Sustained agonist stimulation regulates the development and progression of hypertension and hypertrophy processes through posttranscriptional, short-term and transcriptional , ong-term mechanisms involving metalloproteinases such as MMP-7 and ADAM-12	Rattus norvegicus
physiological function	MMP-7 controls the transcription of the disintegrin and metalloproteinase-12, ADAM-12, the major metalloproteinase implicated in cardiac hypertrophy. Matrix metalloproteinase-7 and ADAM-12 form a novel signaling axis in a variety of cardiovascular processes, including hypertension and hypertrophy, overview. Induction of acute hypertension by vasoconstrictors, i.e. catecholamines, angiotensin II, and the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester, require the posttranscriptional activation of vascular MMP-7. Sustained agonist stimulation regulates the development and progression of hypertension and hypertrophy processes through posttranscriptional, short-term and transcriptional, long-term mechanisms involving metalloproteinases such as MMP-7 and ADAM-12	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)